VEGF Trap-Eye active against DME

Article

A single intravitreal injection of 4.0 mg vascular endothelial growth factor (VEGF) Trap-Eye is associated with bioactivity against diabetic macular oedema (DME), according to study results published in the January issue of the British Journal of Ophthalmology.

A single intravitreal injection of 4.0 mg vascular endothelial growth factor (VEGF) Trap-Eye is associated with bioactivity against diabetic macular oedema (DME), according to study results published in the January issue of the British Journal of Ophthalmology.

Dr P. A. Campochiaro of the Wilmer Eye Institute at the Johns Hopkins University, Baltimore, Maryland, US and colleagues treated DME patients (n=5) with a single VEGF Trap-Eye injection followed by six weeks of observation, during which the team assessed safety and biological activity. Pre-injection, each patient had a foveal thickness (FTH) of 250 µm (median excess central 1 mm FTH = 108 µm), with best-corrected visual acuity (BCVA) between 20/40 and 20/320; median BCVA was 36 ETDRS letters at 4 m (Snellen equivalent, 20/50).

Throughout the follow-up period, no ocular toxicity was observed in any of the patients. Four weeks after injection, the median excess FTH was 59 µm, with a median BCVA improvement of nine letters. By the end of the six-week follow-up period, four patients demonstrated an improvement in excess FTH (median reduction from baseline, 31%), and four demonstrated BCVA improvement (median improvement, three letters).

The researchers therefore concluded that the VEGF Trap-Eye injection was safe, as well as being associated with reduction in foveal thickness and improvement in corrected visual acuity in DME patients.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
Related Content
© 2025 MJH Life Sciences

All rights reserved.